PERSPECTIVE THERAPEUTICS, INC. (CATX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2023-12-31..
Gross margin
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 1.43M USD | Gross Profit |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2023-12-31 | $1.43M | (m) | (m) | (m) |
| 2023-09-30 | $1.88M | (m) | $6.29M | (m) |
| 2023-06-30 | $1.55M | (m) | $6.15M | (m) |
| 2023-03-31 | $2.23M | (m) | (m) | (m) |
| 2022-12-31 | $3.18M | (m) | $5.78M | (m) |
| 2022-09-30 | $4.00M | (m) | $5.95M | (m) |
| 2022-06-30 | $4.62M | $10.79M | $6.18M | 42.76% |
| 2022-03-31 | $5.04M | (m) | $5.96M | (m) |
| 2021-12-31 | $4.96M | (m) | $5.73M | (m) |
| 2021-09-30 | $4.90M | (m) | $5.33M | (m) |
| 2021-06-30 | $5.12M | $10.05M | $4.93M | 50.94% |
| 2021-03-31 | $4.85M | (m) | $4.78M | (m) |
| 2020-12-31 | $5.19M | (m) | $4.71M | (m) |
| 2020-09-30 | $5.13M | (m) | $4.62M | (m) |
| 2020-06-30 | $5.12M | $9.68M | $4.56M | 52.93% |
| 2020-03-31 | $4.93M | (m) | $4.39M | (m) |
| 2019-12-31 | $4.11M | (m) | $4.26M | (m) |
| 2019-09-30 | $3.76M | (m) | $4.31M | (m) |
| 2019-06-30 | $3.05M | $7.31M | $4.27M | 41.66% |
| 2019-03-31 | $2.60M | (m) | $4.39M | (m) |
| 2018-12-31 | $2.33M | $6.64M | $4.31M | 35.16% |
| 2018-09-30 | $2.10M | $6.27M | $4.17M | 33.49% |
| 2018-06-30 | $1.84M | $5.92M | $4.08M | 31.10% |
| 2018-03-31 | $1.90M | (m) | (m) | (m) |
| 2017-12-31 | $1.59M | (m) | (m) | (m) |
| 2017-09-30 | $1.05M | (m) | (m) | (m) |
| 2017-06-30 | $838.00K | (m) | (m) | (m) |
| 2017-03-31 | $292.15K | (m) | (m) | (m) |
| 2016-12-31 | $66.15K | (m) | (m) | (m) |
| 2016-09-30 | $94.15K | (m) | (m) | (m) |
| 2016-06-30 | $129.15K | (m) | (m) | (m) |
| 2016-03-31 | $381.64K | (m) | (m) | (m) |
| 2015-12-31 | $370.53K | (m) | (m) | (m) |
| 2015-09-30 | $305.65K | (m) | (m) | (m) |
| 2015-06-30 | $167.39K | (m) | (m) | (m) |
| 2015-03-31 | $-173.73K | (m) | (m) | (m) |
| 2014-12-31 | $-178.02K | (m) | (m) | (m) |
| 2014-09-30 | $-173.97K | (m) | (m) | (m) |
| 2014-06-30 | $-196.47K | (m) | (m) | (m) |
| 2014-03-31 | $83.02K | (m) | (m) | (m) |
| 2013-12-31 | $218.01K | (m) | (m) | (m) |
| 2013-09-30 | $93.29K | (m) | (m) | (m) |
| 2013-06-30 | $150.18K | (m) | (m) | (m) |
| 2013-03-31 | $240.60K | (m) | (m) | (m) |
| 2012-12-31 | $258.91K | (m) | (m) | (m) |
| 2012-09-30 | $616.44K | (m) | (m) | (m) |
| 2012-06-30 | $703.20K | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | $1.16M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |